Allergan Archives - CFO

After 21 Years and a Spinoff, Profitability Finally Arrives

After 21 Years and a Spinoff, Profitability Finally Arrives

Ironwood Pharmaceuticals is in the black for the first time thanks to its complex spinoff of pre-commercial drug development programs.

By David McCann | September 24, 2019

Big Health Care Companies Are Undervalued

Investor Relations

Big Health Care Companies Are Undervalued

McKesson and Walgreens are strong, healthy companies, despite recent downturns in their stock prices, a CEO in the investment field says.

By David McCann | July 1, 2019

Botox Maker Allergan Sold to AbbVie for $63B

Botox Maker Allergan Sold to AbbVie for $63B

AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.

By Lauren Muskett | June 25, 2019

Proposals to Separate Joint CEO-Board Chair Roles Go Nowhere

Risk & Compliance

Proposals to Separate Joint CEO-Board Chair Roles Go Nowhere

Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.

By Joseph Kieffer | July 12, 2018

Biotech CFO Pitches Fundamentals, not Financials

Biotech CFO Pitches Fundamentals, not Financials

Ironwood’s Tom Graney tries to focus investors on the firm’s pipeline rather than its revenue.

By David Katz | June 28, 2017

Allergan Buys CoolSculpting Company for $2.4B

Allergan Buys CoolSculpting Company for $2.4B

The acquisition of Zeltiq Aesthetics' system for using cooling to eliminate fat cells gives Allergan access to the growing body-contouring market.

By Matthew Heller | February 13, 2017

Allergan Fined $15M Over Disclosure Failures

Risk & Compliance

Allergan Fined $15M Over Disclosure Failures

The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.

By Matthew Heller | January 18, 2017

Allergan Bets on Tobira’s Liver Disease Drug

Allergan Bets on Tobira’s Liver Disease Drug

The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.

By Matthew Heller | September 20, 2016

Pfizer Makes Cancer Play With Medivation Deal

Pfizer Makes Cancer Play With Medivation Deal

The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.

By Matthew Heller | August 22, 2016

Pfizer Adds Eczema Gel With $5B Anacor Deal

Pfizer Adds Eczema Gel With $5B Anacor Deal

If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.

By Katie Kuehner-Hebert | May 16, 2016

Finance Roundup for Executives

Corporate Finance

Finance Roundup for Executives

Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.

By Kerry Maruna | April 7, 2016

Did Treasury Target Pfizer-Allergan Inversion?

Did Treasury Target Pfizer-Allergan Inversion?

The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.

By David Katz and Katie Kuehner-Hebert | April 6, 2016

Clinton to Propose Crackdown on Inversions

Clinton to Propose Crackdown on Inversions

The presidential candidate would impose an "exit tax" on tax inversion deals that let U.S. firms reduce their taxes by merging with companies overseas.

By Matthew Heller | December 7, 2015

Pfizer Buys Allergan for $160B

Pfizer Buys Allergan for $160B

The companies predict the combined entity would have more than $25 billion in operating cash flow starting in 2018.

By Katie Kuehner-Hebert | November 23, 2015

Activist Investor Can’t Dodge Insider Trading Suit

Risk & Compliance

Activist Investor Can’t Dodge Insider Trading Suit

A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.

By Matthew Heller | November 12, 2015